Author(s): Nicola Goekbuget, Hervé Dombret, Gerhard Zugmaier, et. al. EHA Library. Goekbuget N. Jun 16, 2019; 267373; S1619 Abstract: S1619 Session topic: 2. Acute lymphoblastic leukemia – Clinical Background MRD is the strongest predictor of relapse in BCP-ALL. Blinatumomab is a bispecific immunotherapy that redirects T cells to kill CD19+ target cells....
Pro zobrazení tohoto obsahu je třeba být přihlášen.